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Fatty-acid amide hydrolase polymorphisms and post-
traumatic stress disorder after penetrating brain injury
M Pardini1,2,3, F Krueger4,5, M Koenigs6, V Raymont7,8, C Hodgkinson9, S Zoubak9, D Goldman9 and J Grafman1,10
The past few years have seen an increase in the clinical awareness of post-traumatic stress disorder (PTSD), one of the most
disabling and least understood behavioral disorders. Although the biological bases of PTSD are poorly understood, fatty-acid
amide hydrolase (FAAH) activity has been linked with arousability and aversive-memories extinction, that is, two key features of
PTSD. In this study, we investigated the association between the FAAH genetic polymorphisms and PTSD development and
maintenance. We assessed PTSD frequency in a group of male Vietnam war veterans who suffered combat-related penetrating
traumatic brain injury, that is, a relatively homogeneous population regarding the nature of the events that led to PTSD.
We showed that rs2295633, a single-nucleotide polymorphism of FAAH, was significantly associated with PTSD diagnosis in
subjects without lesions in the ventromedial prefrontal cortex. Moreover, the presence of the C allele was associated with more
severe re-experiencing of trauma and more negative reported childhood experiences. In conclusion, our data suggest that FAAH
has an important role in PTSD through modulation of aversive memories and point to both a novel therapeutic target and a
possible risk marker for this condition.
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Introduction
Post-traumatic stress disorder (PTSD) is a behavioral
disorder characterized by recurrent re-experiencing of the
trauma, avoidance of trauma reminders, and elevated arousal
that develop after exposure to a traumatic event.1 One
unresolved issue in our understanding of PTSD is the
relationship between the exposure to a traumatic event and
the development of the disorder. Indeed, although the lifetime
risk of developing PTSD is around 8%,2 the lifetime risk to be
exposed to psychological traumatic events is much higher,
ranging in different studies between 60 and 90%.2,3 Cognitive
theories of PTSD point to a heightened sensibility to trauma
and to an impairment of aversive memories extinction as two
key factors of PTSD development and maintenance.4
Although the biological factors underlying PTSD are still
poorly understood, recent data suggest that the brain
endocannabinoid system has a role in this condition.5,6
Indeed, in animal studies an increase of endocannabinoid
transmission has been shown to improve extinction of
conditioned fear to aversive stimuli and to reduce
anxiety-related behaviors.7,8 Moreover, pharmacological
modulation of endocannabinoid tone has been proposed as
a possible target for anxiety spectrum disorders, such
as PTSD.5
On the basis of this evidence, we investigated the
association between PTSD development and maintenance
and the genetic polymorphisms of fatty-acid amide hydrolase
(FAAH). FAAH is an integral membrane enzyme that is
primarily responsible for the degradation of the endocanna-
binoids in the brain. Moreover, its activity has been linked with
aversive memory processing7 and arousability,6 two of the
cognitive processes altered in PTSD. To shed light on the role
of FAAH in PTSD, we assessed PTSD frequency in a group of
male Vietnam war veterans, who suffered combat-related
penetrating traumatic brain injury (PTBI).9 This population
presents with some unique advantages such as the long
follow-up period, the extensive cognitive and behavioral pre-
injury and post-injury medical data and the relative homo-
geneity regarding the nature of the events that led to PTSD
development, that is, suffering PTBI during their service in
Vietnam.9,10
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Methods
Subject enrollment and PTSD evaluation. Enrolled
subjects were drawn from the Vietnam Head Injury Study
(VHIS) Phase III registry as described elsewhere.11 We
conducted Phase III between 2003 and 2006 at Bethesda
National Naval Medical Center (36–39 years post-injury).
PTBI subjects enrolled in the VHIS registry were included in
the study if they agreed to undergo genetic analysis for FAAH
polymorphisms and if their medical history was negative for
alcohol or substance-abuse disorder, dementia, mood or
psychotic disorder as assessed by clinical data. Our
experimental sample thus consisted of 115 male Caucasian
Vietnam war veterans recruited from the VHIS registry. Each
subject underwent neurological and psychiatric examinations
and a non-contrast brain CT scan. Psychiatric examination
was aimed to verify the presence of other behavioral
disorders and to enquiry on early psychological negative
experiences. The presence and extent of early negative
experiences was evaluated with the Early Trauma Inventory
(ETI), clinician version,12 a semi-structured interview widely
used to quantify negative life-events in childhood and
adolescence Pre-injury characteristics and clinical follow-up
data of the participants were available from military and
Veterans Administration records. PTSD was evaluated using
the Structured Clinical Interview for DSM-IV-TR Axis I
disorders13 and the Clinician-Administered PTSD Scale.14
All subjects gave informed consent to the study. Our
institution ethics committee approved all the study
procedures.
CT acquisition and analysis. Axial non-contrast CT scans
were acquired on a GE Medical Systems Light Speed Plus
CT scanner in helical mode. Images were reconstructed with
an in-plane voxel size of 0.4 mm 0.4 mm, overlapping slice
thickness of 2.5 mm and a 1 mm slice interval. Lesion
location and volume were determined from CT images by
manual tracing using the Analysis of Brain Lesion (ABLe)15
software implemented in MEDx v3.44 (Medical Numerics)
with enhancements to support the Automated Anatomical
Labeling atlas. A trained neuropsychiatrist (VR) performed
the tracings, which were then reviewed by an experienced
observer (JG), who was blind to the results of the clinical
evaluations. The skull and scalp components of the CT
volume were then removed; each volume was spatially
normalized to a de-skulled CT scan, which was previously
spatially normalized to match the shape of the T1 MNI brain
(standard of the International Consortium for Brain Mapping).
The ABLe program was used to exclude the manually
delineated lesion from the spatial normalization process to
improve registration accuracy. Spatial normalization was
performed using an automated image registration algorithm
using a 12-parameter affine model on de-skulled CT scans.
Ventromedial prefrontal cortex (vmPFC) territories were then
identified on CT images according to a previous publication.9
In particular, a subject was included in the vmPFC group if he
showed a lesion encompassing at least 15% of the vmPFC
territory, otherwise he was included in the vmPFC lesion-free
group.9
Genotyping. Enrolled subjects were genotyped for seven
tagging single-nucleotide polymorphisms (SNPs) at FAAH
(rs913168, rs6703669, rs3766246, rs324420, rs324419,
rs2295633, rs7524148) included in a published genetic
array as previously described.16
Statistical analysis. On the basis of our previous finding9
showing that lesions to the vmPFC significantly reduced
PTSD prevalence, we analyzed the effect of FAAH SNP on
PTSD separately for subjects with and without vmPFC
lesions. In these experimental groups, the association
between FAAH SNPs and PTSD diagnosis was evaluated
using chi-square statistics. Differences both in PTSD
symptomatology according to DSM-IV-TR PTSD clusters
and in early psychological negative experiences were
assessed with non-parametric tests for between FAAH
rs2295633 C/- and T/T groups using Mann–Whitney U
tests. Statistical threshold was set at 0.05 (two-tailed,
Bonferroni-corrected for multiple comparisons).
Results
FAAH SNPs and PTSD prevalence. First, we investigated
whether any of the FAAH SNPs were associated with an
increase in PTSD diagnosis separately for those subjects
with and without vmPFC lesions, given the known role of
vmPFC areas in modulating PTSD risk.9 In TPBI subjects
without vmPFC lesions, rs2295633 was the only FAAH SNP
to reveal a significant difference in PTSD prevalence
between the ancestral/– vs variant/variant subjects
(Supplementary Table 1). C/– (Ancestral/– subjects,
compared with T/T (Variant/Variant) subjects, presented
with a higher PTSD diagnosis prevalence (20 PTSDþ out
of 43 subjects vs 5 PTSDþ out of 37 subjects; 46.5% vs
13.5%; chi-square¼ 10.1; P¼ 0.001; Figure 1).
This observed higher prevalence of PTSD diagnosis for the
C/- subjects was not due to differences in cognitive deficits
in other domains or demographic differences. They were
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Figure 1 Prevalence of PTSDþ subjects according to FAAH rs2295633 SNP
genotype in those subjects with an intact vmPFC.
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matched in age (t¼ 0.78; P¼ 0.8) depressive levels (Beck
Depression Inventory, 2nd edition) (t¼ 0.68; P¼ 0.5),17 pre-
injury intelligence (Armed Forces Qualification Test),
(t¼ 0.72; P¼ 0.6),18 education (t¼ 0.82; P¼ 0.6) emotional
intelligence (Mayer–Salovey–Caruso Emotional Intelligence
Test) (t¼ 0.42; P¼ 0.8),19 memory performance (Wechsler
Memory Scale 3rd edition total score) (t¼ 0.65; P¼ 0.8),20
and percentage of total brain damage (t¼ 0.58; P¼ 0.5)
(Supplementary Table 2). Moreover, all the subjects included
in the two aforementioned experimental groups were of
Caucasian ethnicity.
No FAAH SNPs revealed any significant difference in PTSD
prevalence between the ancestral/– vs variant/variant groups
when analyzing only those subjects with vmPFC lesions
(Supplementary Table 1). PTSD distribution in the vmPFC
lesion group for the rs2295633 SNP was 3 subjects out of 20
for the C/– genotype and 3 subjects out of 13 for the T/T
genotype (chi-square¼ 0.35; P¼ 0.55). Lesion distribution
differences between the two experimental lesion groups are
reported in Figure 2.
FAAH rs2295633 SNP and PTSD symptomatology. Given
these results, the following analyses were limited to the
rs2295633 SNP (C/– vs T/T). We thus examined the
differences in PTSD clinical symptomatology between
C/- and T/T subjects starting with those without vmPFC
damage. In this group, C/- subjects showed significantly
more PTSD cluster ‘B’ symptoms according to the DSM-IV-
TR diagnostic criteria (persistent re-experiencing of the
traumatic event)1 than T/T subjects both taking into
account only those patients with a PTSD clinical diagnosis
(2.8±0.3 vs 1.1±0.1; P¼ 0.005; z¼2.73; Figure 3) or the
whole experimental group (2.0±0.2 vs 0.7±0.2; P¼ 0.004;
z¼2.86). There was no difference in the frequency of
cluster ‘C’ (avoidance) (PTSDþ subjects: P¼ 0.63;
z¼0.4. All subjects: P¼ 0.4; z¼0.8) and cluster ‘D’
(arousal) (PTSDþ subjects: P¼ 0.58; z¼0.6. All subjects:
P¼ 0.85; z¼0.78) symptoms between the two genotypes.
Moreover, taking into account the whole sample of patients
with vmPFC damage, there were no differences in frequency
of cluster ‘B’ (P¼ 0.4; z¼0.9), ‘C’ (P¼ 0.6; z¼1.6), or ‘D’
(P¼ 0.5; z¼0.8) symptoms.
FAAH rs2295633 SNP and early experiences. Then, given
the observed effect of FAAH SNP on re-experiencing of the
traumatic event, we determined whether individual genetic
differences in the FAAH gene were also linked with more
intense recollections of negative childhood events. This
analysis was run only in the group without vmPFC damage,
given the observed low prevalence of PTSD in the vmPFC
lesion group. Our data showed that in the C/- group PTSDþ
subjects presented with more severe recollections of early
psychological trauma compared with PTSD subjects (as
assessed with the ETI;12 6.35±0.8 vs 2.0±0.4; z¼2.67;
P¼ 0.005; Figure 3) in the absence of the differences in
emotional aptitude (MSCEIT; P¼ 0.3), total pre-injury
Figure 2 Lesions distribution map for the vmPFC lesion and for the vmPFC lesion-free groups. In red are shown those areas relatively more damaged in the vmPFC group
compared with the vmPFC lesion-free group, whereas in blue are shown those areas relatively more damaged in the vmPFC lesion-free group compared with the vmPFC
lesion group.
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intelligence (P¼ 0.2) or memory scores (P¼ 0.5) between
the two subgroups. In the T/T group there was no difference
in ETI scores between T/T PTSDþ and T/T PTSD subjects
(5.6±1.2 vs 4.6±0.7; P¼ 0.3).
Discussion
Our findings suggest that a FAAH genetic polymorphism
modulates PTSD risk in PTBI subjects with intact vmPFC but
not in those subjects with vmPFC lesions. Presence of the
wild-type allele at this SNP was linked with an increase of
recollections of the traumatic event. Lastly, we showed that
negative early experiences increased PTSD risk only in those
subjects presenting at least one wild-type allele.
To date, the relationship between the presence of the
C (that is wild-type allele) and FAAH function is not com-
pletely understood. Recent data from an amphetamine
challenge study linked a heightened arousability to the
C allele; increased arousal has been linked with reduced
FAAH activity in animal models thus suggesting possible
higher FAAH activity in C allele carriers compared with T allele
carriers.6
Published data on FAAH activity showed that FAAH
inhibition and thus increase of endocannabinoid levels has
been linked with heightened aversive memory extinction
and reduced anxiety levels in animal studies.7,8 Moreover
reduction of endocannabinoid activity has been linked with
impairments of extinction of aversive memories and increased
anxiety levels.8
Our observation of an effect of FAAH only in those subjects
with an intact vmPFC seems to be consistent with a role of
vmPFC in traumatic events recollection and with our previous
observation of a protective effect of vmPFC lesions on PTSD.9
Indeed in neuroimaging studies, recollection of traumatic
events in PTSD subjects has been linked with vmPFC
functions.19,20 Moreover aversive memory consolidation and
extinction has been linked with prefrontal functions both in
animal and human studies,21,22 thus damage to the neural
structures linked with aversive memories extinction would
likely overshadow the relatively more modest effects of a
single SNP on consolidation and extinction processes. This
observation is compatible with our previous report of the need
of intact prefrontal structures to allow for genetic influences to
modulate aggressive behaviors in PTBI.10
One of the major challenges in the current approach to
PTSD is the identification of reliable markers for the factors
that lead to an increased risk for developing the disorder (that
is vulnerability) and of those that lead to a persistence of the
disorder (that is maintenance). Identification of vulnerability
markers could be a key factor in the development of primary
prevention of PTSD in selected populations. Our data suggest
that the FAAH rs2295633 SNP could serve as a possible
marker for increased PTSD risk in subjects exposed to brain
injury and combat experiences; future studies are warranted
to explore the clinical utility of FAAH genotyping to guide
primary prevention of PTSD in other at-risk populations. In
addition, it would be helpful to understand the epigenetic/
environmental factors that might have led those patients with
an increased risk not to develop PTSD.
Moreover, our data suggest that PTSD subjects presents
different clinical and psychopathological characteristics ac-
cording to FAAH genotype, with C/- subjects showing more
intense recollections of traumatic events and of negative
childhood experiences. Given the key role of extinction
learning and of early experiences in different psychother-
apeutic approaches to PTSD, FAAH genotyping could help to
develop individualized therapies based on different genetic
characteristics for the more severe and challenging cases
of PTSD.
In conclusion, our findings point to FAAH as a contributor to
PTSD after PTBI, possibly through the modulation of aversive
memories by extinction processes. These data suggest a role
for endocannabinoid signaling in the development and
maintenance of PTSD and hint at the therapeutic potential
of endocannabinoid systems-modulating drugs for PTSD
patients.5
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Figure 3 Upper panel: traumatic event re-experiencing symptomatology
according to DSM-IV-TR (B ‘Cluster’ PTSD symptoms) distribution and according
to FAAH rs2295633 SNP genotype in PTSDþ subjects with intact vmPFC cortex.
Lower panel: childhood negative events (ETI scale) distribution according to FAAH
rs2295633 SNP genotype in PTSDþ subjects with intact vmPFC cortex.
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